William Federici - Zynerba Pharmaceuticals Director Nominee
| ZYNEDelisted Stock | USD 1.30 0.04 3.17% |
Director
Mr. William J. Federici is an Independent Director of the Company. William J. Federici has served as a member of our Board since August 2015. Mr. Federici has served as senior vice president and chief financial officer of West Pharmaceutical Services, Inc., a publicly traded global pharmaceutical technology company, since August 2003. He served as a memberof the board of directors and chairman of the Audit committee at NuPathe from January 2011 until February 2014. From June 2002 until August 2003, he was national industry director for pharmaceuticals of KPMG LLP, and prior thereto, he was an audit partner with Arthur Andersen, LLP since 2015.
| Age | 57 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 484 581 7505 |
| Web | https://www.zynerba.com |
Zynerba Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4511) % which means that it has lost $0.4511 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8713) %, meaning that it created substantial loss on money invested by shareholders. Zynerba Pharmaceuticals' management efficiency ratios could be used to measure how well Zynerba Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 334.43 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Zynerba Pharmaceuticals has a current ratio of 6.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Zynerba Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Zynerba Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zynerba Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zynerba to invest in growth at high rates of return. When we think about Zynerba Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Antaine Furlong | FSD Pharma Class | 40 | |
| Robert Nostrand | Intracellular Th | 61 | |
| David Urban | FSD Pharma Class | N/A | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Gwen Melincoff | Collegium Pharmaceutical | 65 | |
| Jon Saxe | Durect | 81 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Sam Gejdenson | Phibro Animal Health | 70 | |
| Christopher Alafi | Intracellular Th | 54 | |
| Vladimir Klacar | FSD Pharma Class | N/A | |
| Jun Zheng | China SXT Pharmaceuticals | 46 | |
| Dennis Walsh | Deciphera Pharmaceuticals LLC | 50 | |
| Scott LLB | Lucy Scientific Discovery | 54 | |
| John Martin | Deciphera Pharmaceuticals LLC | 57 | |
| David Hirsch | Collegium Pharmaceutical | 47 | |
| Donal Carroll | FSD Pharma Class | 42 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| Armand Neukermans | Durect | 73 | |
Management Performance
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 |
Zynerba Pharmaceuticals Leadership Team
Elected by the shareholders, the Zynerba Pharmaceuticals' board of directors comprises two types of representatives: Zynerba Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zynerba. The board's role is to monitor Zynerba Pharmaceuticals' management team and ensure that shareholders' interests are well served. Zynerba Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zynerba Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Baron, CFO, Treasurer | ||
| Ray Mannion, Vice President - Manufacturing | ||
| Albert II, Chief Sec | ||
| Daniel Kisner, Director Nominee | ||
| Brian Boyd, Vice President - Manufacturing | ||
| William Federici, Director Nominee | ||
| Liza Squires, Chief Medical Officer | ||
| Suzanne Hanlon, VP of HR, General Counsel and Secretary | ||
| Kenneth Moch, Director Nominee | ||
| Joseph Apostolico, VP HR | ||
| Thomas Harrison, Director Nominee | ||
| Brian Rosenberger, Vice President - Commercial | ||
| James Fickenscher, CFO, Vice President - Corporate Development | ||
| Nancy Tich, Vice President - Clinical | ||
| Warren Cooper, Director | ||
| Armando MBA, Chairman CEO | ||
| Armando Anido, Chairman and CEO | ||
| Cynthia Rask, Director Nominee | ||
| William Roberts, Vice President - Investor Relations and Corporate Communications | ||
| John Butler, Independent Director | ||
| Pamela Stephenson, Independent Director | ||
| Terri Sebree, President |
Zynerba Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zynerba Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Shares Owned By Insiders | 6.07 % | |||
| Shares Owned By Institutions | 12.12 % | |||
| Number Of Shares Shorted | 419.98 K | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |